Bio-Techne CFO gets 22,438 and 36,459 RSUs
BIO-TECHNE Corp (TECH) reported that CFO James Hippel received two equity awards on 2026-08-17: grants of 22,438 Restricted Stock Units and 36,459 Restricted Stock Units, each representing a contingent right to one share of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
BIO-TECHNE Corp (TECH) reported that CFO James Hippel received two equity awards on 2026-08-17: grants of 22,438 Restricted Stock Units and 36,459 Restricted Stock Units, each representing a contingent right to one share of common stock. According to the vesting footnotes, 7,479 RSUs vest on each of 8/17/2027 and 8/17/2028, and 7,480 vest on 8/17/2029 for the first award, while the second award of 36,459 RSUs vests on 8/17/2029. Hippel also holds multiple stock option positions on BIO-TECHNE common stock with exercise prices between $53.60 and $120.46 and expirations from 2027 through 2035, and directly holds 170,183 shares of common stock.
Insider Trade Summary
Grant/Award: 58,897 shares
Grant/Award
15 txns
Insider
Hippel James
Role
CFO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restricted Stock Units F5, F11 | 22,438 | $0.00 | $0.00 |
| Grant/Award | Restricted Stock Units F5, F12 | 36,459 | $0.00 | $0.00 |
| holding | Stock Options (Right to Buy) F1 | -- | -- | -- |
| holding | Stock Options (Right to Buy) F1 | -- | -- | -- |
| holding | Stock Options (Right to Buy) F1 | -- | -- | -- |
| holding | Stock Options (Right to Buy) F1 | -- | -- | -- |
| holding | Stock Options (Right to Buy) F2 | -- | -- | -- |
| holding | Stock Options (Right to Buy) F3 | -- | -- | -- |
| holding | Stock Options (Right to Buy) F4 | -- | -- | -- |
| holding | Performance Restricted Stock Units F5, F6 | -- | -- | -- |
| holding | Performance Restricted Stock Units F5, F7 | -- | -- | -- |
| holding | Restricted Stock Units F5, F8 | -- | -- | -- |
| holding | Restricted Stock Units F5, F9 | -- | -- | -- |
| holding | Restricted Stock Units F5, F10 | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Restricted Stock Units — 95,804 contracts for 36,907 underlying shares (Direct);
Stock Options (Right to Buy) — 371,388 contracts (Direct);
Performance Restricted Stock Units — 53,482 contracts (Direct);
Common Stock — 170,183 shares (Direct)
Footnotes (12)
- F1. Fully exercisable.
- F2. Options to purchase 11,481 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027, and options to purchase 11,480 shares vest on 8/15/2026.
- F3. Options to purchase 8,104 shares vest on each of 8/15/2025, 8/15/2026 and 8/15/2027, and options to purchase 8,105 shares vest on 8/15/2028.
- F4. Options to purchase 12,544 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2028.
- F5. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock.
- F6. Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- F7. Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- F8. 4,011 restricted stock units vest on 8/15/2027.
- F9. 11,545 restricted stock units vest on 11/1/2026; and 11,544 restricted stock units vest on 11/1/2027.
- F10. 4,903 restricted stock units vest on 8/15/2027, and 4,904 restricted stock units vest on 8/15/2028.
- F11. 7,479 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 7,480 restricted stock units vest on 8/17/2029.
- F12. 36,459 restricted stock units vest on 8/17/2029.
Key Figures
RSU grant 1: 22,438 units
RSU grant 2: 36,459 units
Common stock held: 170,183 shares
+5 more
8 metrics
RSU grant 1
22,438 units
Restricted Stock Units granted 2026-08-17; each unit equals one common share
RSU grant 2
36,459 units
Restricted Stock Units granted 2026-08-17; each unit equals one common share
Common stock held
170,183 shares
Direct BIO-TECHNE common stock ownership reported as of 2026-08-17
Option exercise price
$66.97 per share
Stock options on 167,328 underlying common shares expiring 2027-08-05
Option exercise price
$120.46 per share
Stock options on 40,536 underlying common shares expiring 2028-08-06
Option exercise price
$53.60 per share
Stock options on 37,632 underlying common shares expiring 2035-08-15
Performance RSUs holding
24,062 units
Performance Restricted Stock Units outstanding, subject to performance-based vesting
Performance RSUs holding
29,420 units
Additional Performance Restricted Stock Units outstanding, subject to performance-based vesting
Key Terms
Restricted Stock Units, Performance Restricted Stock Units, Stock Options (Right to Buy), exercise price
4 terms
Restricted Stock Units financial
"Each restricted stock unit represents a contingent right to receive one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Performance Restricted Stock Units financial
"Vests in full or in part on 8/15/2027 if certain performance goals"
Performance restricted stock units (PRSUs) are promises to deliver company shares to employees or executives only if the business meets specific performance targets and any time-based holding rules. Think of them as a bonus that converts into stock only after set goals are reached, so investors watch PRSUs for two reasons: they can dilute existing shares if paid out, and they signal how closely management’s pay is tied to company performance.
Stock Options (Right to Buy) financial
"Stock Options (Right to Buy) with specified exercise prices and expiration dates"
exercise price financial
"conversion_or_exercise_price of 53.6000, 74.9100, 84.6100 and other levels"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did BIO-TECHNE (TECH) CFO James Hippel report in this Form 4 filing?
CFO James Hippel reported two grants of Restricted Stock Units, for 22,438 and 36,459 units, each unit representing one share of BIO-TECHNE common stock. He also disclosed existing holdings of stock options and 170,183 directly held common shares.
How many Restricted Stock Units did TECH CFO James Hippel receive on 2026-08-17?
On 2026-08-17, James Hippel received 22,438 and 36,459 Restricted Stock Units. Each RSU is a contingent right to one BIO-TECHNE common share, subject to future vesting based on time and, for some units, performance goals.
What are the key vesting dates for James Hippel’s new RSU awards at BIO-TECHNE (TECH)?
For the 22,438-unit award, 7,479 RSUs vest on 8/17/2027 and 8/17/2028, and 7,480 vest on 8/17/2029. The separate 36,459-unit RSU award vests in full on 8/17/2029, subject to the award terms.
What stock option positions did BIO-TECHNE (TECH) CFO James Hippel report?
Hippel reported several stock option positions on BIO-TECHNE common stock with exercise prices from $53.60 to $120.46 and expirations between 2027 and 2035, covering tens of thousands of underlying shares as detailed in the derivative holdings summary.
Do the reported TECH Form 4 transactions involve any stock sales by James Hippel?
No stock sales are reported; the only transactions are acquisitions of Restricted Stock Units. The filing also lists existing option, RSU, and performance RSU holdings, plus directly held common shares, without any sale or disposition codes.
AI-generated analysis. How Rhea-AI works. Not financial advice.
